三阴性乳腺癌精准治疗研究的新进展与未来展望

肖玉铃; 朱秀之; 江一舟; 邵志敏

doi:10.19401/j.cnki.1007-3639.2022.08.001

您当前的位置：

首页 >

文章列表页 >

三阴性乳腺癌精准治疗研究的新进展与未来展望

专家述评 | 更新时间：2025-12-31

- 三阴性乳腺癌精准治疗研究的新进展与未来展望
- New research advances and future prospect in precision treatment of triple-negative breast cancer
- 中国癌症杂志 2022年32卷第8期页码：669-679
- 作者机构：
  
  复旦大学附属肿瘤医院乳腺外科/复旦大学乳腺癌研究所,复旦大学上海医学院肿瘤学系,上海 200032
- 作者简介：
  
  [ "肖玉铃（ORCID：0000-0002-3684-0816）,复旦大学附属肿瘤医院博士研究生,E-mail: 16307130351@fudan.edu.cn。" ]
  [ "邵志敏,主任医师,教授,首批教育部长江学者特聘教授,国家杰出青年科学基金项目获得者,复旦大学特聘教授。现任复旦大学肿瘤研究所所长、乳腺癌研究所所长,大外科主任兼乳腺外科主任,曾任中国抗癌协会乳腺癌专业委员会主任委员,中国抗癌协会靶向治疗专业委员会主任委员,中华医学会肿瘤学分会副主任委员,第八届亚洲乳腺癌协会主席,St.Gallen乳腺癌大会专家团成员。主要从事乳腺癌的临床和基础研究,建立适合中国人群的早期筛查和诊疗流程,确立三阴性乳腺癌“复旦分型”和精准治疗策略,开展临床试验改善患者预后。已在Cancer Cell、Cell Metabolism、Cell Research、Journal of Clinical Oncology、JAMA Oncology、Journal of the National Cancer Institute等重要期刊上发表论著500余篇,被引用逾8 000次,主编专著10部。多次获得国家科技进步二等奖,教育部科技进步一、二等奖,卫健委科技进步一等奖,上海市科技进步一、二、三等奖,领衔团队入选教育部创新团队。先后主持国家自然科学基金重大项目、十五攻关课题,卫生部临床重点项目等国家级及省部级项目50余项。" ]
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2022.08.001
  中图分类号： R737.9
- 收稿：2022-06-20，
  
  修回：2022-07-10，
  
  纸质出版：2022-08-30
- 稿件说明：
移动端阅览
肖玉铃, 朱秀之, 江一舟, 等. 三阴性乳腺癌精准治疗研究的新进展与未来展望[J]. 中国癌症杂志, 2022,32(8):669-679.

Yuling XIAO, Xiuzhi ZHU, Yizhou JIANG, et al. New research advances and future prospect in precision treatment of triple-negative breast cancer[J]. China Oncology, 2022, 32(8): 669-679.
肖玉铃, 朱秀之, 江一舟, 等. 三阴性乳腺癌精准治疗研究的新进展与未来展望[J]. 中国癌症杂志, 2022,32(8):669-679. DOI： 10.19401/j.cnki.1007-3639.2022.08.001.

Yuling XIAO, Xiuzhi ZHU, Yizhou JIANG, et al. New research advances and future prospect in precision treatment of triple-negative breast cancer[J]. China Oncology, 2022, 32(8): 669-679. DOI： 10.19401/j.cnki.1007-3639.2022.08.001.

摘要

世界卫生组织国际癌症研究机构最新发布的数据显示

乳腺癌现已取代肺癌成为全球发病率最高的恶性肿瘤。三阴性乳腺癌（triple-negative breast cancer

TNBC）是雌激素受体（estrogen receptor

ER）、孕激素受体（progesterone receptor

PR）和人表皮生长因子受体2（human epidermal growth factor receptor 2

HER2）表达均为阴性的乳腺癌

与其他分子分型的乳腺癌相比

TNBC具有易复发转移、整体预后差等特点。TNBC对内分泌治疗及抗HER2治疗不敏感

化疗是其主要的系统治疗手段。随着基因组学、转录组学、代谢组学、蛋白组学、微生物组学的蓬勃发展及对TNBC分子分型的深入研究

针对不同靶点的靶向治疗药物和针对免疫检查点的免疫治疗药物的出现

如多聚腺苷二磷酸核糖聚合酶[poly(ADP-ribose) polymerase

PARP]抑制剂、人滋养细胞表面抗原2（trophoblast cell-surface antigen 2

TROP-2）抗体药物偶联物、pembrolizumab、atezolizumab、durvalumab等

已为TNBC的治疗提供新的手段

正在改变TNBC的临床实践。“精准治疗”“分类而治”是未来发展的方向。本文以TNBC的分子分型为基础

对其靶向治疗和免疫治疗研究的新进展进行归纳总结

以期为今后TNBC精准治疗策略提供参考。

Abstract

According to the latest data released by the Cancer Research Institute of the World Health Organization

breast cancer has replaced lung cancer as the malignant tumor with the highest incidence rate in the world. Triple-negative breast cancer (TNBC) is defined by a lack of estrogen receptor (ER)

progesterone receptor (PR)

and human epidermal growth factor receptor 2 (HER2). Compared with other types of breast cancer

TNBC bears the characteristics of high metastasis rate

strong invasiveness and poor prognosis. TNBC is not sensitive to endocrine therapy and anti-HER2 therapy

and chemotherapy is its main systemic treatment. With the vigorous development of genomics

transcriptomics

metabolomics

proteomics

microbiomics technologies and the in-depth study of TNBC molecular subtyping

targeted therapy and immunotherapy drugs

including poly(ADP-ribose) polymerase (PARP) inhibitors

trophoblast cell-surface antigen 2 (TROP-2) antibody-drug conjugate

pembrolizumab

atezolizumab

durvalumab

etc.

have provided new therapeutic methods

which are changing the clinical practice and treatment pattern of TNBC. It is believed accurate therapy will become a new direction of development in the future. Based on the molecular subtypes of TNBC

here we summarized the research advances in targeted therapy and immunotherapy of TNBC

in order to provide reference for the precise treatment strategy of TNBC in the future.

关键词

Keywords

references

SUNG H , FERLAY J , SIEGEL R L , et al . Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J ] . CA Cancer J Clin , 2021 , 71 ( 3 ): 209 - 249 . DOI: 10.3322/caac.21660 http://doi.org/10.3322/caac.21660 https://onlinelibrary.wiley.com/doi/10.3322/caac.21660 https://onlinelibrary.wiley.com/doi/10.3322/caac.21660

JIANG Y Z , MA D , SUO C , et al . Genomic and transcriptomic landscape of triple-negative breast cancers: subtypes and treatment strategies [J ] . Cancer Cell , 2019 , 35 ( 3 ): 428 - 440 .e5. DOI: 10.1016/j.ccell.2019.02.001 http://doi.org/10.1016/j.ccell.2019.02.001 https://linkinghub.elsevier.com/retrieve/pii/S1535610819300960 https://linkinghub.elsevier.com/retrieve/pii/S1535610819300960

CHO B , HAN Y N , LIAN M , et al . Evaluation of racial/ethnic differences in treatment and mortality among women with triple-negative breast cancer [J ] . JAMA Oncol , 2021 , 7 ( 7 ): 1016 - 1023 . DOI: 10.1001/jamaoncol.2021.1254 http://doi.org/10.1001/jamaoncol.2021.1254 https://jamanetwork.com/journals/jamaoncology/fullarticle/2780032 https://jamanetwork.com/journals/jamaoncology/fullarticle/2780032

YIN L , DUAN J J , BIAN X W , et al . Triple-negative breast cancer molecular subtyping and treatment progress [J ] . Breast Cancer Res , 2020 , 22 ( 1 ): 61 . DOI: 10.1186/s13058-020-01296-5 http://doi.org/10.1186/s13058-020-01296-5 https://doi.org/10.1186/s13058-020-01296-5 https://doi.org/10.1186/s13058-020-01296-5

LEHMANN B D , BAUER J A , CHEN X , et al . Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies [J ] . J Clin Invest , 2011 , 121 ( 7 ): 2750 - 2767 . DOI: 10.1172/JCI45014 http://doi.org/10.1172/JCI45014 http://www.jci.org/articles/view/45014 http://www.jci.org/articles/view/45014

LEHMANN B D , JOVANOVIĆ B , CHEN X , et al . Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection [J ] . PLoS One , 2016 , 11 ( 6 ): e0157368.

BURSTEIN M D , TSIMELZON A , POAGE G M , et al . Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer [J ] . Clin Cancer Res , 2015 , 21 ( 7 ): 1688 - 1698 . DOI: 10.1158/1078-0432.CCR-14-0432 http://doi.org/10.1158/1078-0432.CCR-14-0432 https://aacrjournals.org/clincancerres/article/21/7/1688/248479/Comprehensive-Genomic-Analysis-Identifies-Novel https://aacrjournals.org/clincancerres/article/21/7/1688/248479/Comprehensive-Genomic-Analysis-Identifies-Novel

ZHAO S , MA D , XIAO Y , et al . Molecular subtyping of triple-negative breast cancers by immunohistochemistry: molecular basis and clinical relevance [J ] . Oncologist , 2020 , 25 ( 10 ): e1481-e1491.

JIANG Y Z , LIU Y , XIAO Y , et al . Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial [J ] . Cell Res , 2021 , 31 ( 2 ): 178 - 186 . DOI: 10.1038/s41422-020-0375-9 http://doi.org/10.1038/s41422-020-0375-9 https://doi.org/10.1038/s41422-020-0375-9 https://doi.org/10.1038/s41422-020-0375-9

CHEN L , JIANG Y Z , WU S Y , et al . Famitinib with camrelizumab and nab-paclitaxel for advanced immunomodulatory triple-negative breast cancer (FUTURE-C-plus): an open-label, single-arm, phase Ⅱ trial [J ] . Clin Cancer Res , 2022 , 28 ( 13 ): 2807 - 2817 . DOI: 10.1158/1078-0432.CCR-21-4313 http://doi.org/10.1158/1078-0432.CCR-21-4313 https://aacrjournals.org/clincancerres/article/28/13/2807/704995/Famitinib-with-Camrelizumab-and-Nab-Paclitaxel-for https://aacrjournals.org/clincancerres/article/28/13/2807/704995/Famitinib-with-Camrelizumab-and-Nab-Paclitaxel-for

WU S Y , XU Y , CHEN L , et al . Combined angiogenesis and PD-1 inhibition for immunomodulatory TNBC: concept exploration and biomarker analysis in the FUTURE-C-Plus trial [J ] . Mol Cancer , 2022 , 21 ( 1 ): 84 . DOI: 10.1186/s12943-022-01536-6 http://doi.org/10.1186/s12943-022-01536-6 https://doi.org/10.1186/s12943-022-01536-6 https://doi.org/10.1186/s12943-022-01536-6

NOORDERMEER S M , VAN ATTIKUM H . PARP inhibitor resistance: a tug-of-war in BRCA -mutated cells [J ] . Trends Cell Biol , 2019 , 29 ( 10 ): 820 - 834 . DOI: 10.1016/j.tcb.2019.07.008 http://doi.org/10.1016/j.tcb.2019.07.008 https://linkinghub.elsevier.com/retrieve/pii/S0962892419301242 https://linkinghub.elsevier.com/retrieve/pii/S0962892419301242

CORTESI L , RUGO H S , JACKISCH C . An overview of PARP inhibitors for the treatment of breast cancer [J ] . Target Oncol , 2021 , 16 ( 3 ): 255 - 282 . DOI: 10.1007/s11523-021-00796-4 http://doi.org/10.1007/s11523-021-00796-4 https://doi.org/10.1007/s11523-021-00796-4 https://doi.org/10.1007/s11523-021-00796-4

ROBSON M , IM S A , SENKUS E , et al . Olaparib for metastatic breast cancer in patients with a germline BRCA mutation [J ] . N Engl J Med , 2017 , 377 ( 6 ): 523 - 533 . DOI: 10.1056/NEJMoa1706450 http://doi.org/10.1056/NEJMoa1706450 http://www.nejm.org/doi/10.1056/NEJMoa1706450 http://www.nejm.org/doi/10.1056/NEJMoa1706450

ROBSON M E , TUNG N , CONTE P , et al . OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician & #x02019;s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer [J ] . Ann Oncol , 2019 , 30 ( 4 ): 558 - 566 . DOI: 10.1093/annonc/mdz012 http://doi.org/10.1093/annonc/mdz012 https://linkinghub.elsevier.com/retrieve/pii/S0923753419311111 https://linkinghub.elsevier.com/retrieve/pii/S0923753419311111

TUTT A N J , GARBER J , GELBER R D , et al . VP1-2022: pre-specified event driven analysis of overall survival (OS) in the OlympiA phase & #x02162; trial of adjuvant olaparib (OL) in germline BRCA 1/2 mutation (gBRCAm) associated breast cancer [J ] . Ann Oncol , 2022 , 33 ( 5 ): 566 - 568 . DOI: 10.1016/j.annonc.2022.03.008 http://doi.org/10.1016/j.annonc.2022.03.008 https://linkinghub.elsevier.com/retrieve/pii/S0923753422003866 https://linkinghub.elsevier.com/retrieve/pii/S0923753422003866

TUTT A N J , GARBER J E , KAUFMAN B , et al . Adjuvant olaparib for patients with BRCA 1- or BRCA 2-mutated breast cancer [J ] . N Engl J Med , 2021 , 384 ( 25 ): 2394 - 2405 . DOI: 10.1056/NEJMoa2105215 http://doi.org/10.1056/NEJMoa2105215 http://www.nejm.org/doi/10.1056/NEJMoa2105215 http://www.nejm.org/doi/10.1056/NEJMoa2105215

MCGUIRE K P , ARTHUR D W , MAMOUNAS E P . Updates on management of hereditary breast cancer: new data on PARP inhibitors change recommendations regarding the multidisciplinary care of breast cancer patients with BRCA mutations [J ] . Ann Surg Oncol , 2022 : 2022Jun18.

LITTON J K , RUGO H S , ETTL J , et al . Talazoparib in patients with advanced breast cancer and a germline BRCA mutation [J ] . N Engl J Med , 2018 , 379 ( 8 ): 753 - 763 . DOI: 10.1056/NEJMoa1802905 http://doi.org/10.1056/NEJMoa1802905 http://www.nejm.org/doi/10.1056/NEJMoa1802905 http://www.nejm.org/doi/10.1056/NEJMoa1802905

LITTON J K , BECK J T , JONES J M , et al . Neoadjuvant talazoparib in patients with germline BRCA 1/2 ( gBRCA 1/2) mutation-positive, early HER2-negative breast cancer (BC): results of a phase 2 study [J ] . J Clin Oncol , 2021 , 39 ( 15_suppl ): 505 . DOI: 10.1016/S0959-8049(02)00743-8 http://doi.org/10.1016/S0959-8049(02)00743-8 https://linkinghub.elsevier.com/retrieve/pii/S0959804902007438 https://linkinghub.elsevier.com/retrieve/pii/S0959804902007438

KHOURY K , FELDMAN R , POHLMANN P R , et al . Molecular characterization of trophoblast cell surface antigen 2 (Trop-2) positive triple negative breast cancer (TNBC) [J ] . J Clin Oncol , 2019 , 37 ( 15_suppl ): e14651.

VRANIC S , GATALICA Z . Trop-2 protein as a therapeutic target: a focused review on Trop-2-based antibody-drug conjugates and their predictive biomarkers [J ] . Bosn J Basic Med Sci , 2022 , 22 ( 1 ): 14 - 21 .

BARDIA A , MAYER I A , VAHDAT L T , et al . Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer [J ] . N Engl J Med , 2019 , 380 ( 8 ): 741 - 751 . DOI: 10.1056/NEJMoa1814213 http://doi.org/10.1056/NEJMoa1814213 http://www.nejm.org/doi/10.1056/NEJMoa1814213 http://www.nejm.org/doi/10.1056/NEJMoa1814213

WAHBY S , FASHOYIN-AJE L , OSGOOD C L , et al . FDA approval summary: accelerated approval of sacituzumab govitecan-hziy for third-line treatment of metastatic triple-negative breast cancer [J ] . Clin Cancer Res , 2021 , 27 ( 7 ): 1850 - 1854 . DOI: 10.1158/1078-0432.CCR-20-3119 http://doi.org/10.1158/1078-0432.CCR-20-3119 https://aacrjournals.org/clincancerres/article/27/7/1850/671880/FDA-Approval-Summary-Accelerated-Approval-of https://aacrjournals.org/clincancerres/article/27/7/1850/671880/FDA-Approval-Summary-Accelerated-Approval-of

BARDIA A , TOLANEY S M , PUNIE K , et al . Biomarker analyses in the phase Ⅲ ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer [J ] . Ann Oncol , 2021 , 32 ( 9 ): 1148 - 1156 . DOI: 10.1016/j.annonc.2021.06.002 http://doi.org/10.1016/j.annonc.2021.06.002 https://linkinghub.elsevier.com/retrieve/pii/S0923753421020470 https://linkinghub.elsevier.com/retrieve/pii/S0923753421020470

BARDIA A , HURVITZ S A , TOLANEY S M , et al . Sacituzumab govitecan in metastatic triple-negative breast cancer [J ] . N Engl J Med , 2021 , 384 ( 16 ): 1529 - 1541 . DOI: 10.1056/NEJMoa2028485 http://doi.org/10.1056/NEJMoa2028485 http://www.nejm.org/doi/10.1056/NEJMoa2028485 http://www.nejm.org/doi/10.1056/NEJMoa2028485

MIRICESCU D , TOTAN A , STANESCU-SPINU I I , et al . PI3K/AKT/mTOR signaling pathway in breast cancer: from molecular landscape to clinical aspects [J ] . Int J Mol Sci , 2020 , 22 ( 1 ): E173 .

JANKU F , YAP T A , MERIC-BERNSTAM F . Targeting the PI3K pathway in cancer: are we making headway? [J ] . Nat Rev Clin Oncol , 2018 , 15 ( 5 ): 273 - 291 . DOI: 10.1038/nrclinonc.2018.28 http://doi.org/10.1038/nrclinonc.2018.28 http://www.nature.com/articles/nrclinonc.2018.28 http://www.nature.com/articles/nrclinonc.2018.28

AGOSTINETTO E , EIGER D , PUNIE K , et al . Emerging therapeutics for patients with triple-negative breast cancer [J ] . Curr Oncol Rep , 2021 , 23 ( 5 ): 57 . DOI: 10.1007/s11912-021-01038-6 http://doi.org/10.1007/s11912-021-01038-6 https://doi.org/10.1007/s11912-021-01038-6 https://doi.org/10.1007/s11912-021-01038-6

KALINSKY K , HONG F X , MCCOURT C K , et al . Effect of capivasertib in patients with an AKT 1 E17K-mutated tumor: NCI-MATCH subprotocol EAY131-Y nonrandomized trial [J ] . JAMA Oncol , 2021 , 7 ( 2 ): 271 - 278 . DOI: 10.1001/jamaoncol.2020.6741 http://doi.org/10.1001/jamaoncol.2020.6741 https://jamanetwork.com/journals/jamaoncology/fullarticle/2774443 https://jamanetwork.com/journals/jamaoncology/fullarticle/2774443

SCHMID P , ABRAHAM J , CHAN S , et al . Capivasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer: the PAKT trial [J ] . J Clin Oncol , 2020 , 38 ( 5 ): 423 - 433 .

KIM S B , DENT R , IM S A , et al . Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial [J ] . Lancet Oncol , 2017 , 18 ( 10 ): 1360 - 1372 . DOI: 10.1016/S1470-2045(17)30450-3 http://doi.org/10.1016/S1470-2045(17)30450-3 https://linkinghub.elsevier.com/retrieve/pii/S1470204517304503 https://linkinghub.elsevier.com/retrieve/pii/S1470204517304503

OLIVEIRA M , SAURA C , NUCIFORO P , et al . FAIRLANE, a double-blind placebo-controlled randomized phase Ⅱ trial of neoadjuvant ipatasertib plus paclitaxel for early triple-negative breast cancer [J ] . Ann Oncol , 2019 , 30 ( 8 ): 1289 - 1297 . DOI: 10.1093/annonc/mdz177 http://doi.org/10.1093/annonc/mdz177 https://linkinghub.elsevier.com/retrieve/pii/S0923753419312918 https://linkinghub.elsevier.com/retrieve/pii/S0923753419312918

RICCARDI C , NAPOLITANO E , PLATELLA C , et al . Anti-VEGF DNA-based aptamers in cancer therapeutics and diagnostics [J ] . Med Res Rev , 2021 , 41 ( 1 ): 464 - 506 . DOI: 10.1002/med.21737 http://doi.org/10.1002/med.21737 https://onlinelibrary.wiley.com/doi/10.1002/med.21737 https://onlinelibrary.wiley.com/doi/10.1002/med.21737

VON MINCKWITZ G , EIDTMANN H , REZAI M , et al . Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer [J ] . N Engl J Med , 2012 , 366 ( 4 ): 299 - 309 . DOI: 10.1056/NEJMoa1111065 http://doi.org/10.1056/NEJMoa1111065 http://www.nejm.org/doi/10.1056/NEJMoa1111065 http://www.nejm.org/doi/10.1056/NEJMoa1111065

SHEPHERD J H , BALLMAN K , POLLEY M C , et al . CALGB 40603 (alliance): long-term outcomes and genomic correlates of response and survival after neoadjuvant chemotherapy with or without carboplatin and bevacizumab in triple-negative breast cancer [J ] . J Clin Oncol , 2022 , 40 ( 12 ): 1323 - 1334 . DOI: 10.1200/JCO.21.01506 http://doi.org/10.1200/JCO.21.01506 https://ascopubs.org/doi/10.1200/JCO.21.01506 https://ascopubs.org/doi/10.1200/JCO.21.01506

CAMERON D , BROWN J , DENT R , et al . Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial [J ] . Lancet Oncol , 2013 , 14 ( 10 ): 933 - 942 . DOI: 10.1016/S1470-2045(13)70335-8 http://doi.org/10.1016/S1470-2045(13)70335-8 https://linkinghub.elsevier.com/retrieve/pii/S1470204513703358 https://linkinghub.elsevier.com/retrieve/pii/S1470204513703358

MILLER K D , O’NEILL A , GRADISHAR W , et al . Double-blind phase Ⅲ trial of adjuvant chemotherapy with and without bevacizumab in patients with lymph node-positive and high-risk lymph node-negative breast cancer (E5103) [J ] . J Clin Oncol , 2018 , 36 ( 25 ): 2621 - 2629 . DOI: 10.1200/JCO.2018.79.2028 http://doi.org/10.1200/JCO.2018.79.2028 https://ascopubs.org/doi/10.1200/JCO.2018.79.2028 https://ascopubs.org/doi/10.1200/JCO.2018.79.2028

KONO M , FUJII T , LIM B , et al . Androgen receptor function and androgen receptor-targeted therapies in breast cancer: a review [J ] . JAMA Oncol , 2017 , 3 ( 9 ): 1266 - 1273 . DOI: 10.1001/jamaoncol.2016.4975 http://doi.org/10.1001/jamaoncol.2016.4975 http://oncology.jamanetwork.com/article.aspx?doi=10.1001/jamaoncol.2016.4975 http://oncology.jamanetwork.com/article.aspx?doi=10.1001/jamaoncol.2016.4975

SALVI S , BONAFÈ M , BRAVACCINI S . Androgen receptor in breast cancer: a wolf in sheep’s clothing? A lesson from prostate cancer [J ] . Semin Cancer Biol , 2020 , 60 : 132 - 137 . DOI: 10.1016/j.semcancer.2019.04.002 http://doi.org/10.1016/j.semcancer.2019.04.002 https://linkinghub.elsevier.com/retrieve/pii/S1044579X19300550 https://linkinghub.elsevier.com/retrieve/pii/S1044579X19300550

GUCALP A , TOLANEY S , ISAKOFF S J , et al . Phase Ⅱ trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic breast cancer [J ] . Clin Cancer Res , 2013 , 19 ( 19 ): 5505 - 5512 . DOI: 10.1158/1078-0432.CCR-12-3327 http://doi.org/10.1158/1078-0432.CCR-12-3327 https://aacrjournals.org/clincancerres/article/19/19/5505/78041/Phase-II-Trial-of-Bicalutamide-in-Patients-with https://aacrjournals.org/clincancerres/article/19/19/5505/78041/Phase-II-Trial-of-Bicalutamide-in-Patients-with

TRAINA T A , MILLER K , YARDLEY D A , et al . Enzalutamide for the treatment of androgen receptor-expressing triple-negative breast cancer [J ] . J Clin Oncol , 2018 , 36 ( 9 ): 884 - 890 . DOI: 10.1200/JCO.2016.71.3495 http://doi.org/10.1200/JCO.2016.71.3495 https://ascopubs.org/doi/10.1200/JCO.2016.71.3495 https://ascopubs.org/doi/10.1200/JCO.2016.71.3495

TARANTINO P , CARMAGNANI PESTANA R , CORTI C , et al . Antibody-drug conjugates: smart chemotherapy delivery across tumor histologies [J ] . CA Cancer J Clin , 2022 , 72 ( 2 ): 165 - 182 . DOI: 10.3322/caac.21705 http://doi.org/10.3322/caac.21705 https://onlinelibrary.wiley.com/doi/10.3322/caac.21705 https://onlinelibrary.wiley.com/doi/10.3322/caac.21705

INDINI A , RIJAVEC E , GROSSI F . Trastuzumab deruxtecan: changing the destiny of HER2 expressing solid tumors [J ] . Int J Mol Sci , 2021 , 22 ( 9 ): 4774 . DOI: 10.3390/ijms22094774 http://doi.org/10.3390/ijms22094774 https://www.mdpi.com/1422-0067/22/9/4774 https://www.mdpi.com/1422-0067/22/9/4774

CORTÉS J , KIM S B , CHUNG W P , et al . Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer [J ] . N Engl J Med , 2022 , 386 ( 12 ): 1143 - 1154 . DOI: 10.1056/NEJMoa2115022 http://doi.org/10.1056/NEJMoa2115022 http://www.nejm.org/doi/10.1056/NEJMoa2115022 http://www.nejm.org/doi/10.1056/NEJMoa2115022

MODI S N , SAURA C , YAMASHITA T , et al . Trastuzumab deruxtecan in previously treated HER2-positive breast cancer [J ] . N Engl J Med , 2020 , 382 ( 7 ): 610 - 621 . DOI: 10.1056/NEJMoa1914510 http://doi.org/10.1056/NEJMoa1914510 http://www.nejm.org/doi/10.1056/NEJMoa1914510 http://www.nejm.org/doi/10.1056/NEJMoa1914510

TARANTINO P , HAMILTON E , TOLANEY S M , et al . HER2-low breast cancer: pathological and clinical landscape [J ] . J Clin Oncol , 2020 , 38 ( 17 ): 1951 - 1962 .

MODI S N , JACOT W , YAMASHITA T , et al . Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer [J ] . N Engl J Med , 2022 , 387 ( 1 ): 9 - 20 . DOI: 10.1056/NEJMoa2203690 http://doi.org/10.1056/NEJMoa2203690 http://www.nejm.org/doi/10.1056/NEJMoa2203690 http://www.nejm.org/doi/10.1056/NEJMoa2203690

MAENNLING A E , TUR M K , NIEBERT M , et al . Molecular targeting therapy against EGFR family in breast cancer: progress and future potentials [J ] . Cancers (Basel) , 2019 , 11 ( 12 ): E1826.

SHEN M H , JIANG Y Z , WEI Y , et al . Tinagl1 suppresses triple-negative breast cancer progression and metastasis by simultaneously inhibiting integrin/FAK and EGFR signaling [J ] . Cancer Cell , 2019 , 35 ( 1 ): 64 - 80 .e7. DOI: 10.1016/j.ccell.2018.11.016 http://doi.org/10.1016/j.ccell.2018.11.016 https://linkinghub.elsevier.com/retrieve/pii/S1535610818305373 https://linkinghub.elsevier.com/retrieve/pii/S1535610818305373

BERNSDORF M , INGVAR C , JÖRGENSEN L , et al . Effect of adding gefitinib to neoadjuvant chemotherapy in estrogen receptor negative early breast cancer in a randomized phase Ⅱ trial [J ] . Breast Cancer Res Treat , 2011 , 126 ( 2 ): 463 - 470 . DOI: 10.1007/s10549-011-1352-2 http://doi.org/10.1007/s10549-011-1352-2 http://link.springer.com/10.1007/s10549-011-1352-2 http://link.springer.com/10.1007/s10549-011-1352-2

BASELGA J , GÓMEZ P , GREIL R , et al . Randomized phase Ⅱ study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer [J ] . J Clin Oncol , 2013 , 31 ( 20 ): 2586 - 2592 . DOI: 10.1200/JCO.2012.46.2408 http://doi.org/10.1200/JCO.2012.46.2408 https://ascopubs.org/doi/10.1200/JCO.2012.46.2408 https://ascopubs.org/doi/10.1200/JCO.2012.46.2408

CAREY L A , RUGO H S , MARCOM P K , et al . TBCRC 001: randomized phase Ⅱ study of cetuximab in combination with carboplatin in stage Ⅳ triple-negative breast cancer [J ] . J Clin Oncol , 2012 , 30 ( 21 ): 2615 - 2623 . DOI: 10.1200/JCO.2010.34.5579 http://doi.org/10.1200/JCO.2010.34.5579 https://ascopubs.org/doi/10.1200/JCO.2010.34.5579 https://ascopubs.org/doi/10.1200/JCO.2010.34.5579

LI C J , TZENG Y T , CHIU Y H , et al . Pathogenesis and potential therapeutic targets for triple-negative breast cancer [J ] . Cancers (Basel) , 2021 , 13 ( 12 ): 2978 . DOI: 10.3390/cancers13122978 http://doi.org/10.3390/cancers13122978 https://www.mdpi.com/2072-6694/13/12/2978 https://www.mdpi.com/2072-6694/13/12/2978

AGOSTINETTO E , LOSURDO A , NADER-MARTA G , et al . Progress and pitfalls in the use of immunotherapy for patients with triple negative breast cancer [J ] . Expert Opin Investig Drugs , 2022 , 31 ( 6 ): 567 - 591 . DOI: 10.1080/13543784.2022.2049232 http://doi.org/10.1080/13543784.2022.2049232 https://www.tandfonline.com/doi/full/10.1080/13543784.2022.2049232 https://www.tandfonline.com/doi/full/10.1080/13543784.2022.2049232

WU S Y , WANG H , SHAO Z M , et al . Triple-negative breast cancer: new treatment strategies in the era of precision medicine [J ] . Sci China Life Sci , 2021 , 64 ( 3 ): 372 - 388 . DOI: 10.1007/s11427-020-1714-8 http://doi.org/10.1007/s11427-020-1714-8 https://doi.org/10.1007/s11427-020-1714-8 https://doi.org/10.1007/s11427-020-1714-8

TARANTINO P , ANTONARELLI G , ASCIONE L , et al . Investigational immunomodulatory drugs for enhancement of triple negative breast cancer (TNBC) immunotherapy: early phase development [J ] . Expert Opin Investig Drugs , 2022 , 31 ( 6 ): 499 - 513 . DOI: 10.1080/13543784.2021.1972968 http://doi.org/10.1080/13543784.2021.1972968 https://www.tandfonline.com/doi/full/10.1080/13543784.2021.1972968 https://www.tandfonline.com/doi/full/10.1080/13543784.2021.1972968

NANDA , CHOW L Q , DEES E C , et al . Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ⅰb KEYNOTE-012 study [J ] . J Clin Oncol , 2016 , 34 ( 21 ): 2460 - 2467 . DOI: 10.1200/JCO.2015.64.8931 http://doi.org/10.1200/JCO.2015.64.8931 https://ascopubs.org/doi/10.1200/JCO.2015.64.8931 https://ascopubs.org/doi/10.1200/JCO.2015.64.8931

ADAMS S , SCHMID P , RUGO H S , et al . Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase Ⅱ KEYNOTE-086 study [J ] . Ann Oncol , 2019 , 30 ( 3 ): 397 - 404 . DOI: 10.1093/annonc/mdy517 http://doi.org/10.1093/annonc/mdy517 https://linkinghub.elsevier.com/retrieve/pii/S0923753419310750 https://linkinghub.elsevier.com/retrieve/pii/S0923753419310750

ADAMS S , LOI S , TOPPMEYER D , et al . Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase Ⅱ KEYNOTE-086 study [J ] . Ann Oncol , 2019 , 30 ( 3 ): 405 - 411 . DOI: 10.1093/annonc/mdy518 http://doi.org/10.1093/annonc/mdy518 https://linkinghub.elsevier.com/retrieve/pii/S0923753419310762 https://linkinghub.elsevier.com/retrieve/pii/S0923753419310762

WINER E P , LIPATOV O , IM S A , et al . Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial [J ] . Lancet Oncol , 2021 , 22 ( 4 ): 499 - 511 . DOI: 10.1016/S1470-2045(20)30754-3 http://doi.org/10.1016/S1470-2045(20)30754-3 https://linkinghub.elsevier.com/retrieve/pii/S1470204520307543 https://linkinghub.elsevier.com/retrieve/pii/S1470204520307543

CORTES J , CESCON D W , RUGO H S , et al . Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial [J ] . Lancet , 2020 , 396 ( 10265 ): 1817 - 1828 . DOI: 10.1016/S0140-6736(20)32531-9 http://doi.org/10.1016/S0140-6736(20)32531-9 https://linkinghub.elsevier.com/retrieve/pii/S0140673620325319 https://linkinghub.elsevier.com/retrieve/pii/S0140673620325319

CORTÉS J , CESCON D W , RUGO H S , et al . LBA16 KEYNOTE-355: final results from a randomized, double-blind phase & #x02162; study of first-line pembrolizumab + chemotherapy vs placebo + chemotherapy for metastatic TNBC [J ] . Ann Oncol , 2021 , 32 : S1289-S1290.

HEEKE A L , TAN A R . Checkpoint inhibitor therapy for metastatic triple-negative breast cancer [J ] . Cancer Metastasis Rev , 2021 , 40 ( 2 ): 537 - 547 . DOI: 10.1007/s10555-021-09972-4 http://doi.org/10.1007/s10555-021-09972-4 https://doi.org/10.1007/s10555-021-09972-4 https://doi.org/10.1007/s10555-021-09972-4

SCHMID P , SALGADO R , PARK Y H , et al . Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study [J ] . Ann Oncol , 2020 , 31 ( 5 ): 569 - 581 . DOI: 10.1016/j.annonc.2020.01.072 http://doi.org/10.1016/j.annonc.2020.01.072 https://linkinghub.elsevier.com/retrieve/pii/S0923753420360324 https://linkinghub.elsevier.com/retrieve/pii/S0923753420360324

NANDA , LIU M C , YAU C , et al . Effect of pembrolizumab plus neoadjuvant chemotherapy on pathologic complete response in women with early-stage breast cancer: an analysis of the ongoing phase 2 adaptively randomized I-SPY2 trial [J ] . JAMA Oncol , 2020 , 6 ( 5 ): 676 - 684 . DOI: 10.1001/jamaoncol.2019.6650 http://doi.org/10.1001/jamaoncol.2019.6650 https://jamanetwork.com/journals/jamaoncology/fullarticle/2761193 https://jamanetwork.com/journals/jamaoncology/fullarticle/2761193

SCHMID P , CORTES J , DENT R , et al . Event-free survival with pembrolizumab in early triple-negative breast cancer [J ] . N Engl J Med , 2022 , 386 ( 6 ): 556 - 567 . DOI: 10.1056/NEJMoa2112651 http://doi.org/10.1056/NEJMoa2112651 http://www.nejm.org/doi/10.1056/NEJMoa2112651 http://www.nejm.org/doi/10.1056/NEJMoa2112651

SCHMID P , CORTES J , PUSZTAI L , et al . Pembrolizumab for early triple-negative breast cancer [J ] . N Engl J Med , 2020 , 382 ( 9 ): 810 - 821 . DOI: 10.1056/NEJMoa1910549 http://doi.org/10.1056/NEJMoa1910549 http://www.nejm.org/doi/10.1056/NEJMoa1910549 http://www.nejm.org/doi/10.1056/NEJMoa1910549

SCHMID P , RUGO H S , ADAMS S , et al . Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial [J ] . Lancet Oncol , 2020 , 21 ( 1 ): 44 - 59 . DOI: 10.1016/S1470-2045(19)30689-8 http://doi.org/10.1016/S1470-2045(19)30689-8 https://linkinghub.elsevier.com/retrieve/pii/S1470204519306898 https://linkinghub.elsevier.com/retrieve/pii/S1470204519306898

EMENS L A , ADAMS S , BARRIOS C H , et al . First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis [J ] . Ann Oncol , 2021 , 32 ( 8 ): 983 - 993 . DOI: 10.1016/j.annonc.2021.05.355 http://doi.org/10.1016/j.annonc.2021.05.355 https://linkinghub.elsevier.com/retrieve/pii/S0923753421015556 https://linkinghub.elsevier.com/retrieve/pii/S0923753421015556

MILES D , GLIGOROV J , ANDRÉ F , et al . Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase Ⅲ trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer [J ] . Ann Oncol , 2021 , 32 ( 8 ): 994 - 1004 . DOI: 10.1016/j.annonc.2021.05.801 http://doi.org/10.1016/j.annonc.2021.05.801 https://linkinghub.elsevier.com/retrieve/pii/S0923753421020263 https://linkinghub.elsevier.com/retrieve/pii/S0923753421020263

MITTENDORF E A , ZHANG H , BARRIOS C H , et al . Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial [J ] . Lancet , 2020 , 396 ( 10257 ): 1090 - 1100 . DOI: 10.1016/S0140-6736(20)31953-X http://doi.org/10.1016/S0140-6736(20)31953-X https://linkinghub.elsevier.com/retrieve/pii/S014067362031953X https://linkinghub.elsevier.com/retrieve/pii/S014067362031953X

BACHELOT T , FILLERON T , BIECHE I , et al . Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase Ⅱ SAFIR02-BREAST IMMUNO trial [J ] . Nat Med , 2021 , 27 ( 2 ): 250 - 255 . DOI: 10.1038/s41591-020-01189-2 http://doi.org/10.1038/s41591-020-01189-2 https://doi.org/10.1038/s41591-020-01189-2 https://doi.org/10.1038/s41591-020-01189-2

LOIBL S , UNTCH M , BURCHARDI N , et al . A randomised phase Ⅱ study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study [J ] . Ann Oncol , 2019 , 30 ( 8 ): 1279 - 1288 . DOI: 10.1093/annonc/mdz158 http://doi.org/10.1093/annonc/mdz158 https://linkinghub.elsevier.com/retrieve/pii/S0923753419312785 https://linkinghub.elsevier.com/retrieve/pii/S0923753419312785

TIAN Y G , LI Y L , SHAO Y P , et al . Gene modification strategies for next-generation CAR-T cells against solid cancers [J ] . J Hematol Oncol , 2020 , 13 ( 1 ): 54 . DOI: 10.1186/s13045-020-00890-6 http://doi.org/10.1186/s13045-020-00890-6 https://doi.org/10.1186/s13045-020-00890-6 https://doi.org/10.1186/s13045-020-00890-6

CAR-T cell therapy shows early potential in TNBC [EB/OL ] . 2018 , https://www.onclive.com/view/initial-results-of-car-tcell-therapy-study-show-tolerability-in-vivo-expansion-in-tnbc. https://www.onclive.com/view/initial-results-of-car-tcell-therapy-study-show-tolerability-in-vivo-expansion-in-tnbc https://www.onclive.com/view/initial-results-of-car-tcell-therapy-study-show-tolerability-in-vivo-expansion-in-tnbc

CORTI C , VENETIS K , SAJJADI E , et al . CAR-T cell therapy for triple-negative breast cancer and other solid tumors: preclinical and clinical progress [J ] . Expert Opin Investig Drugs , 2022 , 31 ( 6 ): 593 - 605 . DOI: 10.1080/13543784.2022.2054326 http://doi.org/10.1080/13543784.2022.2054326 https://www.tandfonline.com/doi/full/10.1080/13543784.2022.2054326 https://www.tandfonline.com/doi/full/10.1080/13543784.2022.2054326

SAXENA M , VAN DER BURG S H , MELIEF C J M , et al . Therapeutic cancer vaccines [J ] . Nat Rev Cancer , 2021 , 21 ( 6 ): 360 - 378 . DOI: 10.1038/s41568-021-00346-0 http://doi.org/10.1038/s41568-021-00346-0 https://doi.org/10.1038/s41568-021-00346-0 https://doi.org/10.1038/s41568-021-00346-0

ZHU S Y , YU K D . Breast cancer vaccines: disappointing or promising? [J ] . Front Immunol , 2022 , 13 : 828386 . DOI: 10.3389/fimmu.2022.828386 http://doi.org/10.3389/fimmu.2022.828386 https://www.frontiersin.org/articles/10.3389/fimmu.2022.828386/full https://www.frontiersin.org/articles/10.3389/fimmu.2022.828386/full

MORSE M A , GWIN W R 3rd , MITCHELL D A . Vaccine therapies for cancer: then and now [J ] . Target Oncol , 2021 , 16 ( 2 ): 121 - 152 . DOI: 10.1007/s11523-020-00788-w http://doi.org/10.1007/s11523-020-00788-w https://doi.org/10.1007/s11523-020-00788-w https://doi.org/10.1007/s11523-020-00788-w

VINAYAK S , TOLANEY S M , SCHWARTZBERG L , et al . Open-label clinical trial of niraparib combined with pembrolizumab for treatment of advanced or metastatic triple-negative breast cancer [J ] . JAMA Oncol , 2019 , 5 ( 8 ): 1132 - 1140 . DOI: 10.1001/jamaoncol.2019.1029 http://doi.org/10.1001/jamaoncol.2019.1029 https://jamanetwork.com/journals/jamaoncology/fullarticle/2735888 https://jamanetwork.com/journals/jamaoncology/fullarticle/2735888

PUSZTAI L , YAU C , WOLF D M , et al . Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage Ⅱ/Ⅲ breast cancer: results from the adaptively randomized I-SPY2 trial [J ] . Cancer Cell , 2021 , 39 ( 7 ): 989 - 998 .e5. DOI: 10.1016/j.ccell.2021.05.009 http://doi.org/10.1016/j.ccell.2021.05.009 https://linkinghub.elsevier.com/retrieve/pii/S1535610821002750 https://linkinghub.elsevier.com/retrieve/pii/S1535610821002750

CHIEN A J , GLIWA A S , RAHMAPUTRI S , et al . A phase Ⅰb trial of the cyclin-dependent kinase inhibitor dinaciclib (dina) in combination with pembrolizumab (P) in patients with advanced triple-negative breast cancer (TNBC) and response correlation with Myc-overexpression [J ] . J Clin Oncol , 2020 , 38 ( 15_suppl ): 1076 . DOI: 10.1200/JCO.2020.38.15_suppl.1076 http://doi.org/10.1200/JCO.2020.38.15_suppl.1076 https://ascopubs.org/doi/10.1200/JCO.2020.38.15_suppl.1076 https://ascopubs.org/doi/10.1200/JCO.2020.38.15_suppl.1076

浏览量

5827

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

三阴性乳腺癌脑转移治疗的研究进展

2022年中国乳腺癌重要临床试验成果及最新进展

精准医学时代三阴性乳腺癌治疗的研究进展

靶向治疗及免疫治疗联合化疗为产AFP阳性结肠癌患者带来显著获益1例病例报告并文献复习

转移性结直肠癌三线治疗的研究现状及进展